entity

base editing

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about base editing: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

5Connections
2Hypotheses
2Analyses
5Outgoing
0Incoming
10Experiments
2Debates

No AI portrait yet

Outgoing (5)

TargetRelationTypeStr
DNA double-strand breakssuppressesprocess0.90
PARKINSONtherapeutic_targetdisease0.80
APOEmodulatesgene0.80
Parkinson's Diseasetreatsdisease0.75
Pcsk9regulatesgene0.70

Incoming (0)

SourceRelationTypeStr
No incoming edges

Targeting Hypotheses (2)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
Targeted APOE4-to-APOE3 Base Editing Therapy 0.758 neurodegeneration APOE4 structural biology and therapeutic
Multiplexed Base Editing for Simultaneous Neuroprotective Ge 0.590 neurodegeneration CRISPR-based therapeutic approaches for

Mentioning Analyses (2)

Scientific analyses that reference this entity

CRISPR-based therapeutic approaches for neurodegenerative diseases

neurodegeneration | 2026-04-03 | 14 hypotheses Top: 0.827

CRISPR-based therapeutic approaches for neurodegenerative diseases

neurodegeneration | 2026-04-02 | 0 hypotheses

Experiments (10)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
RBG treatment in ApoE-/- atherosclerosis mouse model validation atherosclerosis 0.900 0.00 ApoE-/- mice proposed N/A
s:** - Biochemical binding assays measuring PROTAC selectivity for APO falsification Neurodegeneration 0.400 0.50 cell_line proposed $100,000
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau clinical Alzheimer's Disease 0.400 0.50 cell_line proposed $180,000
Why Does Amyloid Removal Only Slow Decline 27%? — Mechanistic investig clinical Alzheimer's Disease 0.400 0.50 human proposed $7,100,000
ApoE4 Function in Alzheimer's Disease validation Alzheimer's Disease 0.400 0.50 mouse proposed $360,000
Biomarker-Guided Sequential Therapy Selection in Alzheimer's Disease clinical Alzheimer's Disease 0.400 0.50 human proposed $5,460,000
Blood-Based Biomarker Panel for Early AD Detection clinical Alzheimer's Disease 0.400 0.50 cell_line proposed $220,000
CRISPR Gene Correction Approaches for CBS/PSP clinical Parkinson's Disease 0.400 0.50 human proposed $6,550,000
Down Syndrome Alzheimer's Disease: Mechanisms and Therapeutic Timing clinical Alzheimer's Disease 0.400 0.50 human proposed $7,500,000
Sex Differences in Alzheimer's Disease — mechanisms and therapeutic im clinical Alzheimer's Disease 0.400 0.50 human proposed $7,500,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wid [PMID:38753766] Huang Q, Chan KY, Wu J, Botticello-Romer Science 2024 1
ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. [PMID:36348357] Raulin AC, Doss SV, Trottier ZA, Ikezu T Mol Neurodegener 2022 1
APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485] Serrano-Pozo A, Das S, Hyman BT Lancet Neurol 2021 1
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456] Long JM, Holtzman DM Cell 2019 1
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. [PMID:31367008] Yamazaki Y, Zhao N, Caulfield TR, Liu CC Nat Rev Neurol 2019 1
The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Mic [PMID:28930663] Krasemann S, Madore C, Cialic R, Baufeld Immunity 2017 1
CRISPR-based correction of apolipoprotein E4 in Alzheimer's disease: Therapeutic [PMID:41812941] ["Wang M", "Niu D", "Zhang Q", "Tang Y", International journal of biolo 2026 0
Perioperative polygenic and APOE-based genetic risk assessment for neurocognitiv [PMID:40562635] Thedim M, Hu J, Maher M, Wiener-Kronish Br J Anaesth 2026 0
Increased genetic protection against Alzheimer's disease in centenarians. [PMID:40615639] Bae H, Song Z, Ali A, Sasaki T, Tesi N e Geroscience 2026 0
Integrative machine learning approach to risk prediction for dementia and Alzhei [PMID:40864401] Stern A, Linial M Geroscience 2026 0
Adipose Tissue Macrophage-Derived Proplatelet Basic Protein Exacerbates Psoriasi [PMID:40886963] Zhu L, Du L, Wu J, Ding D, Wang J et al. J Invest Dermatol 2026 0
Targeting KAT8 alleviates vascular senescence by modulating the INHBA/TGF-β path [PMID:41445196] Lin Z, Xiong J, Zhang F, Zhang H, Zhu M Mol Ther 2026 0
Menopause, cognition, and Alzheimer's disease risk. [PMID:41531227] Samudra N, Vemuri M, Weitlauf J Curr Opin Obstet Gynecol 2026 0
Neuropsychiatric symptoms and apolipoprotein E genotypes in neurocognitive disor [PMID:40145985] Lozupone M, Leccisotti I, Mollica A, Ber Neural regeneration research 2026 0
A mechanistic study of mitochondria-targeted PCSK9 liposomes attenuate oxidative [PMID:41906524] Zhang L, Chen G, Bai Y, Li Q Journal of liposome research 2026 0
Brain Single-Cell Transcriptional Responses to Bexarotene-Activated RXR in an Al [PMID:41828651] Saibro-Girardi C, Lu Y, Fitz NF, Gelain International journal of molec 2026 0
Betulinic Acid Attenuates Vascular Smooth Muscle Cell Senescence and Aortic Vasc [PMID:41830286] Lu T, Wang L, Chen S, Wang T, Sun N, Qin Rejuvenation research 2026 0
Association of Periodontal Pathogens and Their Inflammatory Mediators With Alzhe [PMID:41890452] Arriaga P, Vianna K, Montez C, Panariell Cureus 2026 0
Can we refute a role for infections in Alzheimer's disease pathogenesis? [PMID:41867029] Chatila ZK, Duggan MR, Silberberg E, Fer Alzheimer's & dementia : the j 2026 0
Long-Read Transcriptome Sequencing and Functional Validation Reveals Novel and O [PMID:41889903] Rybacki K, Cha ENY, Deutsch HM, Gaudet E bioRxiv : the preprint server 2026 0

Debates (2)

Multi-agent debates referencing this entity

Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for

closed · Rounds: 4 · Score: 0.95 · 2026-04-03

Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for

closed · Rounds: 4 · Score: 0.90 · 2026-04-02

Related Research

Hypotheses and analyses mentioning base editing in their description or question text

No additional research found